

Endocrine Abstracts

May 2025 Volume 110 ISSN 1479-6848 (online)

Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

10-13 May 2025, Copenhagen, Denmark






















Endocrine Abstracts



Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course

10–13 May 2025, Copenhagen, Denmark

Joint Steering Committee (JSC)

JOINT CHAIRS:

Anita Hokken-Koelega (The Netherlands) ESPE President and Jérôme Bertherat (France) ESE President

ESPE Representatives

Peter Kühnen (Germany)
Chair of the ESPE Programme Organising Committee
Mohamad Maghnie (Italy)
Chair of the ESPE Corporate Liaison Board
Rasa Verkauskiene (Lithuania)
Chair of the ESPE Strategic and Finance Committee
Nils Krone & Mehul Dattani (UK)
ESPE Programme Organising Committee Members

ESE Representatives

Cynthia Andoniadou (UK)
ESE Congress Committee Chair
Wiebke Arlt (UK)
ESE President-Elect
Sebastian Neggers (The Netherlands)
ESE Treasurer

Joint Scientific Programme Committee (JSPC)

JOINT CHAIRS:

Peter Kühnen (Germany) Chair of the ESPE Programme Organising Committee and Cynthia Andoniadou (UK) ESE Congress Committee Chair

ESPE Representatives

Nils Krone (UK) Mehul Dattani (UK) Anders Juul (Denmark) Katharina Main (Denmark) Zdeněk Šumník (Czech Republic)

ESPE Programme Committee

Jacques Beltrand (France), Stefano Cianfarani (Italy), Sasha Howard (UK), Rachel Reynaud (France), Paul van Trotsenburg (The Netherlands), Malgorzata Wasniewska (Italy), Ram Weiss (Israel)

Young Endocrinologists (YES) Group Representative: Hussain Alsaffar (Oman)

ESE Representatives

Frederic Castinetti (France) Aylin Hanyaloglou (UK) Martin Fassnacht (Germany) Aleksandra Buha Djordjevic (Serbia) Peter Lommer Kristensen (Denmark)

ESE Programme Committee

Krystallinia Alexandraki (Greece), Matthias Bluher (Germany), Sheerazad Boulkroun (France), Philippe Caron (France), Pauliina Damdimopoulou (Sweden), Silvia Grottolli (Italy), Mojca Jensterle (Slovenia), Gudmunder Johannsson (Sweden), Tim Korevaar (The Netherlands), Raul Luque (Spain), Luis Perez-Rivas (Germany), Flavia Prodram (Italy), Nadia Schoenmakers (UK), Elena Tsourdi (Germany), Elizabeth Winter (The Netherlands), Lina Zabuliene (Lithuania) ESE Young Endocrinologists and Scientists (EYES) Representative: Barbara Altieri (Germany)

Joint Local Organising Committee (JLOC)

Anders Juul (Denmark) Katharina Main (Denmark) Peter Lommer Kristensen (Denmark) Dorte Glintborg (Denmark)

Stina Willemoes Borresen (Denmark) (Chair of the Danish Society of Young Endocrinologists)

Abstract Marking Panel

Abali, Saygin Ahmed, Faisal Aksglaede, Lise Alexandraki, Krystallenia Allgrove, Jeremy Alonso-Magdalena, Paloma Altieri, Barbara Alvarez, Clara

Altert, Barbara
Alvarez, Clara
Audi, Laura
Barlier, Anne
Beuschlein, Felix
Blü her, Matthias
Bolanowski, Marek
Buyukgebiz, Atilla
Caron, Philippe
Castro-Feijoo, Lidia

Castro-Feijoo, Lidia Çetinkaya, Semra Christiansen, Peter Christoforidis, Athanasios Chrousos, George Cianfarani, Stefano Coutant, Regis Craen, Margarta Dahlgren, Jovanna Daly, Adrian

Damdimopoulou, Pauliina

De Sanctis, Luisa Decker, Ralph Delemer, Brigitte Deodati, Annalisa Dumitrescu, Cristina Elbarbary, Nancy Samir Fernandes-Rosa, Fabio Finken, Martijn Gherlan, Iuliana Glasberg, Simona Goulis, Dimitrios Gravholt, Claus Grossman, Ashley D. Guercio, Gabriela

Höybye, Charlotte Hubalewska-Dydejczyk, Alicja

Guran, Tulay

Hubatewska-Dydejczyk, Alicja Ilias, Ioannis Jensterle, Mojca Johannsson, Gudmundur Kanaka-Gantenbein, Christina

Kandaraki, Eleni Kjærsgaard, Per Klee, Philippe Konrade, Ilze Korevaar, Tim Krone, Nils Krsek, Michal Laetitia, Martinerie Le Tissier, Paul Lefebvre, Hervé Leger, Juliane Li, Dong Lim, Sharon

Lips, Paul Livia Gheorghiu, Monica

Llahana, Sofia
Loche, Sandro
Loli, Paola
Luger, Anton
Lungu, Adriancatalin
Luque, Raul M.
M. Winter, Elizabeth

MacKenzie, Scott

Macut, Djuro
Maes, Christa
Maiter, Dominique
Makras, Polyzois
Malecka-tendera, Ewa
Manco, Melania
Mannelli, Massimo
Mantero, Franco
Mantovani, Giovanna
Marazuela, Monica
Marina, Ljiljana
Martin, David

Martínez-Barbera, Juan Pedro

Martins, Ana Sofia Matikainen, Niina McCabe, Christopher McElreavey, Ken Meijer, Onno Mendonca, Berenice Messina, Andrea Messina, Maria Francesca Metherell, Louise Miljic, Dragana Miller, Bradley Minnetti, Marianna Miras, Mirta Beatriz Mitchell, Rod

Mittag, Jens Morin-Papunen, Laure Mortensen, Li Juel Mouritsen, Annette Mukheriee, Abir Murray, Philip Musat, Madalina Muzsnai, Agota Naciu, Anda Mihaela Namba, Noriyuki Neggers, Sebastian Newell-Price, John Nicolaides, Nicolas Niculescu, Dan Alexandru Niedziela, Marek Nikolaou, Nikolaos

Nikolaou, Nikolaos Nixon, Mark Nogueiras, Rubén Nordenström, Anna Obermayer-Pietsch, Barbara Olarescu, Nicoleta Cristina Oliveira, Pedro F: Olsson, Daniel S. Ong, Ken K. Opitz, Robert

Pandey, Amit

Pagotto, Uberto

Papadimitriou, Dimitrios Patocs, Attila Pearce, Simon Pedicelli, Stefania Peeters, Robin Pekic Djurdjevic, Sandra Perez-Rivas, Luis Gustavo

perrild, hans
Perry, Rebecca
Persani, Luca
Perseghin, Gianluca
Peter, Igaz
Pfeifer, Marija

Piekiełko-Witkowska, Agnieszka

Pignatelli, Duarte Pilgaard, Kasper Pilz. Stefan Pohlenz, Joachim Polak, Michel Polyzos, Stergios Popovic, Jadranka Poutanen, Matti Power, Deborah Prasad, Rathi Prevot, Vincent Prodam, Flavia Pruhova Stepanka Pyrzak, Beata Quintos, Jose Bernardo Radian, Serban Ragnarsson, Oskar Rahman, Nafis Raimann, Adalbert Rajpert-De Meyts, Ewa

Rajpert-De Meyts, Ewa Ramhøj, Louise Randell, Tabitha Rauner, Martina Raverot, Gerald Reincke, Martin Rejnmark, Lars Rey, Rodolfo A. Richter-Unruh, Annette

Riedl, Stefan Rizzoti, Karine Robledo, Mercedes

Roman, Gabriella Romijn, Hans Ronchi, Cristina L Ross, Richard

Rogol, Alan

Ross, Richard Ruchala, Marek Rutten, Elizabeth Sachs, Laurent

Salerno, Maria Carolina Samaan M. Constantine

Samaan, M. Constantine Santi, Daniele

Santi, Daniele Saponaro, Federica Saunders, Philippa Scaramuzza, Andrea Schalin-Jantti, Camilla Schepper Jean, De Schopohl, Jochen Schulte, Dominik Schwarz, Peter Semler, Jörg Senniappan, Senthil Shah, Pratik Shaikh, M Guftar Shestakova, Ekaterina

Shestakova, Marina Shimon, Ilan Sikjaer, Tanja Siklar, Zeynep Simoni, Manuela Skae, Mars Skordis, Nicos Söderlund, Sanni Soucek, Ondrej Stalla Gü'nter Karl

Stefanaki, Charikleia Steichen, Elisabeth Stimson, Roland Storbeck, Karl

Steenblock, Charlotte

Street, Maria Sumnik, Zdenek Svensson, Jannet Szinnai, Gabor Tabarin, Antoine Tauschmann, Martin Ten, Svetlana Tena-Sempere, Manuel Tenenbaum-rakover, Yardena

Terzolo, Massimo Theiler-Schwetz, Verena Theodoropoulou, Marily Tigas, Stelios

Timmers, Henri Toledo, Rodrigo Tomlinson, Jeremy Toppari, Jorma Tóth. Miklós Touraine, Philippe Trifanescu, Raluca Tsagarakis, Stylianos Tsourdi, Elena Tzanela, Marinella Uday, Suma Ugege, Modupe Underbjerg, Line Valerio, Giuliana van den Akker, Erica van der Lely, Aart Jan Van Eck, Judith van Hul, Wim van Santen, Hanneke van Trotsenburg, Paul

Vantyghem, Marie-Christine Vassiliadi, Dimitra Vila, Greisa Vilmann, Lea Visser, Edward

Vlachopapadopoulou, Elpis

Volke, Vallo Vukovic, Rade

Wasniewska, Malgorzata

Wass, John
Weiss, Ram
Werther, George
Widimsky, Jiri
Wilding, John
Williams, Tracy Ann
Winter, Elizabeth M.
Wirth, Eva
Wit, Jan Maarten
Witchel, Selma
Woelfle, Joachim
Wójcik, Małgorzata
Wong, Sc

Wood, Claire
Wudy, Stefan
Yadav, Sangita
yavropoulou, maria
yeoh, Phillip
Yildiz, Bulent
Zabuliene, Lina
Zacharin, Margaret
Zandee, Wouter
Zangen, David
Zarkovic, Milos
Zatelli, Maria Chiara
Zennaro, Maria-Christina
Zilaitiene, Birute

Zillikens, Carola

Zwaveling-Soonawala, Nitash

The Joint Congress of ESPE and ESE 2025 would like to thank the following industry partners for their support of the 2025 Congress in Copenhagen.

Platinum sponsors

Ascendis Pharma Merck Novo Nordisk

Gold Sponsors

BioMarin

Pfizer

Sandoz

Bronze Sponsors

Alexion, AstraZeneca Rare Disease

Amgen

BridgeBio

Camurus AB

Chiesi

Crinetics Pharmaceuticals

ESTEVE

Immunovant

Inozyme

Kyowa Kirin International

Mereo Biopharma

Neurocrine Biosciences

Recordati Rare Diseases

Rhythm Pharmaceuticals

Sanofi

Soleno Therapeutics Europe Ltd

Uni-Pharma

Supporter

iCare World

Ipsen

Adrenal and Cardiovascular Endocrinology

JOINT86

A case of mistaken identity: hypoadrenalism and the cirrhotic paradox Maxim Barnett¹, Justin Riley Lam², Carlo Casipit¹ & Ana Rivadeneira Jefferson-Einstein Hospital, Internal Medicine, Philadelphia, United States; ²Jefferson Einstein, Internal Medicine, Philadelphia, United States; ³Jefferson-Einstein Hospital, Philadelphia, United States

Introduction

Persistent hypotension and hyponatremia are common clinical features in patients with cirrhosis, for which an endocrine consult is not uncommon. Additionally, hypoalbuminemia is a common finding in cirrhosis, with reductions in total hormone assay levels, including cortisol, which leads to a false interpretation of hypocortisolemia. Whether or not there is truly an increased risk (or diagnosis) of hypoadrenalism in patients with underlying cirrhosis remains unknown.

The primary objective of this study is to evaluate if cirrhosis is associated with a greater risk for adrenal insufficiency. Secondary objectives include comparing serum levels of albumin, total cortisol, and free cortisol between patients with (and without) cirrhosis, to assess for significant differences

Methods

The study was performed as a retrospective cohort study, with data collated from TriNetX Global Collaborative Network, providing de-identified patient information from 143 healthcare organizations worldwide. Two cohorts were assessed in this study: Group A (patients with cirrhosis who have had a total cortisol measurement, n=43,786) and Group B (patients without cirrhosis who have had total cortisol measurements, n=1,249,256). Propensity score matching was employed to allow for balancing between the cohorts with n = 53, 220; this was achieved by controlling for age, race, gender, body mass index, A1c, alcohol use, systemic corticosteroid use, and underlying inflammatory diseases of the liver. Results

The results of this study noted no greater risk for primary, secondary, tertiary or drug-induced hypoadrenalism in patients with cirrhosis compared to those without, but rather a statistically significant (but likely clinically negligible) reduction in risk (Relative Risk 0.929, 95% CI: 0.872-0.99, P Secondary outcomes noted a significantly lower mean albumin level in Group A (3.171 vs 3.58, P < 0.0001) but higher mean total cortisol (14.06 vs 12.188, P < 0.0001)0.0001). There was no significant difference regarding free cortisol between both cohorts (P = 0.9822).

Conclusion

This study suggests that cirrhosis does not confer a greater risk for adrenal insufficiency (of any cause). As expected, patients with cirrhosis did demonstrate hypoalbuminemia, however, they appeared to overall exhibit higher mean total cortisol levels (without a significant difference in free cortisol). These findings support a cautious approach to adrenal function testing in patients with cirrhosis, and for reserving the diagnosis of adrenal insufficiency when there is true clinical suspicion.

DOI: 10.1530/endoabs.110.EP1

EP2

JOINT1339

Effects of switching from conventional glucocorticoid therapy to modified-release hydrocortisone (MR-HC) on the steroid matabolome

in patients with 21-hydroxylase deficiency <u>Matthias Auer</u>^{1,2}, Lea Tschaidse¹, Ann-Christin Welp¹, Martin Matthias Auer^{1,2}, Lea Tschaidse¹, Ann-Christin Welp¹, Martin Bidlingmaier¹, Sonja Kunz³, Michaela Hartmann³, Stefan Wudy³ &

Nicole Reisch¹ Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich, Germany; ²Medizinisch Klinik und Poliklinik IV, LMU, Munich, Germany; ³Justus-Liebig-University, Division of Pediatric Endocrinology & Diabetology, Laboratory for Translational Hormone Analysis in Pediatric Endocrinology, Steroid Research & Mass Spectrometry Unit, Center of Child and Adolescent Medicine, Giessen, Germany

Background

New hydrocortisone formulations with modified release are increasingly used in treating patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (210HD). The goal is better androgen control while reducing overall glucocorticoid exposure through more physiological hydrocortisone release and replacement. However, the effects of switching from conventional glucocorticoid therapy to modified-release hydrocortisone (MR-HC) on steroid metabolism remain uninvestigated

Methods

The steroid metabolome in 24-h urine samples was analyzed in 22 patients with classic CAH due to 210HD (10 women, 12 men). Before the switch, 10 patients received conventional hydrocortisone, 9 prednisolone, and 3 combination therapy. The switch to MR-HC was performed using equivalent dose conversion (prednisolone conversion factor = 5). Urine samples were collected before and six months after the switch and analyzed using gas chromatography-mass spectrometry (GC-MS).

Results

Based on serum androstenedione and 17-OHP levels, three patients were classified as not well controlled at baseline. After switching, one patient transitioned from well-controlled to not well-controlled, and another showed the opposite trend. Median hydrocortisone-equivalent dosages were 25 mg (IQR 24.375–35.625) before and 27.5 mg (IQR 20–35) after the switch to MR-HC (P= 0.109). The switch led to a trend toward increased major cortisol metabolites $(5\alpha\text{-THF} + \text{THF} + \text{THE}, P = 0.093)$ and overall urinary cortisol metabolites $(5\alpha\text{-THF}+\text{THF}+\text{THE}+a\text{-C}+b\text{-C}+a\text{-Cl}+b\text{-Cl}; P=0.059)$ in those previously on HC. No absolute change in 17-OHP metabolites (Po-5 $\beta3\alpha$, Po-5α3α, PT, 11-OH-P) or significant change in overall 11-oxygenated androgens was observed. In women, 11-deoxygenated androgens showed a declining trend (P = 0.071), leading to a significant increase in the 11-oxygenated (110H-An + 110-An + 110H-Et) to 11-deoxygenated androgen ratio (An + Et + A5-3 β , 17α + A5-3β, 17β + DHEA + 16α -OH-DHEA + A5T- 16α) from 0.64 (IQR 0.24-2.10) to 2.75 (IQR 1.67-5.75, P = 0.007), indicating increased adrenal suppression. In men, no significant change in 11-oxygenated or deoxygenated androgens was found. However, individually, significant PT reductions (6790 vs. 2982 μg/d) were seen in 14/22 patients, 110H-An reductions (828 vs. 426 μg/d) in 12/22, and An reductions (823 vs. 433 μg/d) in 12/22.

Conclusion

While overall glucocorticoid exposure remained comparable, trends toward increased urinary cortisol metabolites suggest a shift in cortisol metabolism, possibly reflecting optimised cortisol availability resulting in increased adrenal androgen suppression. Individual patients of both sexes may therefore benefit from a switch to modified-release hydrocortisone.

DOI: 10.1530/endoabs.110.EP2

EP3

IOINT3739

Echocardiographic evaluation of functional and morphological alterations in obesity: a comparison between obese individuals with and without Metabolic Syndrome

Cvetanka Volkanovska Ilijevska¹, Valentina Andova², Valentina Velkoska Nakova³, Natasha Nedeska Minova⁴, Taner Hasan⁵ & Ljubica Georgievska

¹University Clinic of Endocrinology, Diabetes and Metabolic Disorders SS. Cyril and Methodius University, Skopje, Macedonia; ²University Clinic of Cardiology, Medical Faculty, Ss. Cyril and Methodius, Skopje, Macedonia; ³Faculty of Medical Sciences, Goce Delcev University, Internal medicine, Stip, Macedonia; 4General City Hospital 8 thSeptember, Skopje, Macedonia; ⁵General City Hospital 8th September, Skopje, Macedonia

Background

Obesity has been identified as an independent risk factor for heart failure. The risk of heart failure is dependent on body mass index (BMI).

This study aimed to examine the effects of obesity on myocardial function and morphology, and to compare these alterations in obese individuals with and without metabolic syndrome (MetS+/- group). Methods

A total 125 subjects with a BMI more than 25 kg/m² underwent metabolic and clinical evaluation. An evaluation of conventional echocardiographic parameters and cardiac deformation by 2D speckle tracking echocardiography was conducted. The mean age was 45.0 ± 9.6 years (female: 58.7%), and the average BMI was 35.01 ± 6.53 . In 74% of the subjects, the duration of overweight/obesity was over 10 years. Metabolic syndrome was diagnosed in 54patients (70%). Two dimensional echocardiographic evaluation showed that the group had a larger LA maximal volume and a LA volume indexed for body height than the MetS group, but the differences were not statistically significant (P=0.068, P=0.098, respectively). The MetS group had significantly lower LA ejection fraction compared to the MetS group (LAEF% = 46.89 vs 50.13, P = 0.03). Regarding the strain analysis, it was also found that the ${
m MetS}^+$ group had significantly lower values for the peak longitudinal deformation of LA in the reservoir phase (PALS) (P=0.008). The LV mass